Neoleukin
17 articles about Neoleukin
-
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
9/22/2023
Neoleukin Therapeutics, Inc., today announced that its Board of Directors (“Board”) has approved a reverse stock split of the Company’s outstanding shares of common stock at a ratio of 1-for-5.
-
Neurogene and Neoleukin Announce Definitive Merger Agreement
7/18/2023
Neurogene Inc. and Neoleukin Therapeutics, Inc. announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
-
Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition
3/8/2023
Neoleukin Therapeutics, Inc., today announced that it has engaged SVB Securities to assist in reviewing strategic alternatives for the Company with the goal of maximizing shareholder value.
-
Neoleukin Therapeutics plans to slash its workforce by about 40% and drop NL-201, a de novo IL-2/IL-15 agonist currently in Phase I, according to its third-quarter report.
-
Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update
11/14/2022
Neoleukin Therapeutics, Inc. announced financial results for the third quarter ended September 30, 2022 as well as a strategic decision to discontinue development of NL-201, a fully de novo IL-2/IL-15 agonist, and focus on advancing next-generation de novo protein therapeutics based on Neoleukin's expertise in designing and testing novel cytokine mimetics and experience with advanced machine learning.
-
Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting
11/3/2022
Neoleukin Therapeutics, Inc., “Neoleukin”, announced an oral presentation at the upcoming American Society of Hematology Annual Meeting and Exposition taking place December 10-13, 2022 in New Orleans, Louisiana.
-
Neoleukin Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference
8/3/2022
Neoleukin Therapeutics, Inc., today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 1 p.m. Eastern.
-
Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022
7/27/2022
Neoleukin Therapeutics, Inc., "Neoleukin” (NASDAQ:NLTX), today announced it will report second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of financial markets.
-
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
-
Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA® (pembrolizumab)
5/16/2022
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced treatment of the first patient in a combination arm evaluating the safety and efficacy of Neoleukin’s NL-201 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® .
-
Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference
4/7/2022
Neoleukin Therapeutics, Inc. announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Conference on Thursday, April 14, 2022 at 12:00 p.m. Eastern.
-
Neoleukin Therapeutics Announces Appointment of Donna Cochener as General Counsel
3/15/2022
Neoleukin Therapeutics, Inc., “Neoleukin”, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced the appointment of Donna M. Cochener as General Counsel, Senior Vice President Legal.
-
Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual Meeting
3/8/2022
Neoleukin Therapeutics, Inc., “Neoleukin”, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced three presentations at the upcoming American Association for Cancer Research Annual Meeting taking place April 8-13, 2022 in New Orleans, Louisiana.
-
Clinical Catch-Up: January 10-14
1/17/2022
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look. -
Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021)
12/11/2021
Neoleukin Therapeutics, Inc., “Neoleukin”, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced the presentation of preclinical data on NL-201 in multiple myeloma at the 63rd American Society of Hematology Annual Meeting and Exposition taking place virtually and in person December 11-14, 2021.
-
Neoleukin Therapeutics to Present at Upcoming Investor Conferences
11/9/2021
Neoleukin Therapeutics, Inc., today announced that management will participate in two upcoming investor conferences. Presentation Details: Event: Stifel 2021 Virtual Healthcare Conference Date: Tuesday, November 16, 2021 Time: 3:20 to 3:50 p.m. EST
-
Neoleukin Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Update
11/4/2021
Neoleukin Therapeutics, Inc., today announced financial results and a corporate update for the third quarter ended September 30, 2021.